Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Innoviva Inc (INVA)  
$16.08 0.07 (0.43%) as of 4:30 Wed 5/22


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 101,390,000
Market Cap: 1.63(B)
Last Volume: 668,805 Avg Vol: 666,964
52 Week Range: $12.32 - $16.78
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 215,000 664,000
Total Buy Value $0 $0 $2,804,388 $8,468,005
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 5 12
Total Shares Sold 0 0 10,994 10,994
Total Sell Value $0 $0 $153,810 $153,810
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 1
End Date 2024-02-22 2023-11-21 2023-05-23 2022-05-23

   
Records found: 704
  Page 20 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Winningham Rick E Chief Executive Officer   •       •      –    2011-03-01 4 AS $22.53 $1,439,059 D/D (63,873) 613,652     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-28 4 AS $22.49 $1,544,030 D/D (67,000) 677,525     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-28 4 OE $8.53 $867,436 D/D 101,752 744,525     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-25 4 AS $22.22 $2,070,524 D/D (92,200) 642,773     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-25 4 OE $8.53 $1,158,121 D/D 135,850 734,973     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-24 4 AS $21.45 $1,996,995 D/D (93,100) 599,123     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-24 4 OE $8.53 $1,158,974 D/D 135,950 692,223     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-23 4 AS $21.14 $2,063,264 D/D (97,600) 556,273     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-23 4 OE $8.53 $1,214,813 D/D 142,500 653,873     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-22 4 AS $21.43 $3,624,800 D/D (168,800) 511,373     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-22 4 OE $8.53 $2,200,644 D/D 258,140 680,173     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-02-20 4 D $22.50 $55,800 D/D (2,480) 98,379     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2011-02-20 4 D $22.50 $69,998 D/D (3,111) 367,063     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2011-02-20 4 D $22.50 $72,900 D/D (3,240) 249,382     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-20 4 D $22.50 $152,775 D/D (6,790) 422,033     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2011-02-20 4 D $22.50 $78,998 D/D (3,511) 218,590     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2011-02-18 4 AS $23.12 $85,567 D/D (3,701) 252,622     -
   Young William D Director   –       •      –    2011-02-18 4 S $23.22 $124,831 D/D (5,376) 28,753     -
   Young William D Director   –       •      –    2011-02-18 4 OE $8.53 $91,661 D/D 10,752 34,129     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2011-02-18 4 B $23.70 $3,608,989 I/I 152,278 5,902,278 1.5     -
   Winningham Rick E Chief Executive Officer   •       •      –    2011-02-11 4 A $0.00 $0 D/D 247,500 428,823     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2011-02-11 4 A $0.00 $0 D/D 112,500 370,174     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2011-02-11 4 A $0.00 $0 D/D 112,500 256,323     -
   Brinkley David L Head of Business Dev.   •       –      –    2011-02-11 4 A $0.00 $0 D/D 62,500 100,859     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2011-02-11 4 A $0.00 $0 D/D 112,500 222,101     -
  704 Records found
  Previous  20  21  22  23  24  25  26  27  28  29   
  Page 20 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us